Rappta Therapeutics

Rappta Therapeutics is a private, pre-revenue biotech founded in 2020, advancing a novel class of small molecule therapeutics designed to reactivate the PP2A tumor suppressor. Operating at the lead optimization to late preclinical stage, the company is pioneering a molecular glue approach to target PP2A, offering a new mechanism to combat cancer and potentially other diseases. With a team split between Finland and the US, Rappta is building a platform based on deep structural and biological insights into PP2A inactivation. The company's success hinges on validating this challenging but high-potential target and advancing its lead candidates into clinical development.

Platform for developing molecular glue small molecules that reactivate the protein phosphatase 2A (PP2A) tumor suppressor by modulating protein-protein interactions.

The direct pharmacological reactivation of PP2A is a nascent field with few, if any, clinical-stage competitors, giving Rappta potential first-mover advantage. However, it competes indirectly with all oncology therapeutics and may face future competition from other biotechs or large pharma exploring similar phosphatase-targeting strategies.